Mobile Mitral and Aortic Valvular Masses in Patients With Hereditary Hemorrhagic Telangiectasia Receiving Intravenous Bevacizumab

Bevacizumab is now an emerging treatment option for severe hereditary hemorrhagic telangiectasia–related bleeding including epistaxis and gastrointestinal tract bleeding. The impact of long-term intravenous bevacizumab therapy on cardiac structure and function is unknown. We describe 3 patients rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Albitar, Hasan Ahmad, Almodallal, Yahya, Nishimura, Rick, Iyer, Vivek N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411168/
https://www.ncbi.nlm.nih.gov/pubmed/32793873
http://dx.doi.org/10.1016/j.mayocpiqo.2020.01.002
_version_ 1783568319103631360
author Albitar, Hasan Ahmad
Almodallal, Yahya
Nishimura, Rick
Iyer, Vivek N.
author_facet Albitar, Hasan Ahmad
Almodallal, Yahya
Nishimura, Rick
Iyer, Vivek N.
author_sort Albitar, Hasan Ahmad
collection PubMed
description Bevacizumab is now an emerging treatment option for severe hereditary hemorrhagic telangiectasia–related bleeding including epistaxis and gastrointestinal tract bleeding. The impact of long-term intravenous bevacizumab therapy on cardiac structure and function is unknown. We describe 3 patients receiving intravenous bevacizumab therapy for severe hereditary hemorrhagic telangiectasia–related bleeding who were found to have abnormal mobile masses on the mitral valve (n=2) and aortic valve (n=1). The clinical impact of these findings is unknown and requires further study.
format Online
Article
Text
id pubmed-7411168
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-74111682020-08-12 Mobile Mitral and Aortic Valvular Masses in Patients With Hereditary Hemorrhagic Telangiectasia Receiving Intravenous Bevacizumab Albitar, Hasan Ahmad Almodallal, Yahya Nishimura, Rick Iyer, Vivek N. Mayo Clin Proc Innov Qual Outcomes Case Report Bevacizumab is now an emerging treatment option for severe hereditary hemorrhagic telangiectasia–related bleeding including epistaxis and gastrointestinal tract bleeding. The impact of long-term intravenous bevacizumab therapy on cardiac structure and function is unknown. We describe 3 patients receiving intravenous bevacizumab therapy for severe hereditary hemorrhagic telangiectasia–related bleeding who were found to have abnormal mobile masses on the mitral valve (n=2) and aortic valve (n=1). The clinical impact of these findings is unknown and requires further study. Elsevier 2020-05-08 /pmc/articles/PMC7411168/ /pubmed/32793873 http://dx.doi.org/10.1016/j.mayocpiqo.2020.01.002 Text en © 2020 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Albitar, Hasan Ahmad
Almodallal, Yahya
Nishimura, Rick
Iyer, Vivek N.
Mobile Mitral and Aortic Valvular Masses in Patients With Hereditary Hemorrhagic Telangiectasia Receiving Intravenous Bevacizumab
title Mobile Mitral and Aortic Valvular Masses in Patients With Hereditary Hemorrhagic Telangiectasia Receiving Intravenous Bevacizumab
title_full Mobile Mitral and Aortic Valvular Masses in Patients With Hereditary Hemorrhagic Telangiectasia Receiving Intravenous Bevacizumab
title_fullStr Mobile Mitral and Aortic Valvular Masses in Patients With Hereditary Hemorrhagic Telangiectasia Receiving Intravenous Bevacizumab
title_full_unstemmed Mobile Mitral and Aortic Valvular Masses in Patients With Hereditary Hemorrhagic Telangiectasia Receiving Intravenous Bevacizumab
title_short Mobile Mitral and Aortic Valvular Masses in Patients With Hereditary Hemorrhagic Telangiectasia Receiving Intravenous Bevacizumab
title_sort mobile mitral and aortic valvular masses in patients with hereditary hemorrhagic telangiectasia receiving intravenous bevacizumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411168/
https://www.ncbi.nlm.nih.gov/pubmed/32793873
http://dx.doi.org/10.1016/j.mayocpiqo.2020.01.002
work_keys_str_mv AT albitarhasanahmad mobilemitralandaorticvalvularmassesinpatientswithhereditaryhemorrhagictelangiectasiareceivingintravenousbevacizumab
AT almodallalyahya mobilemitralandaorticvalvularmassesinpatientswithhereditaryhemorrhagictelangiectasiareceivingintravenousbevacizumab
AT nishimurarick mobilemitralandaorticvalvularmassesinpatientswithhereditaryhemorrhagictelangiectasiareceivingintravenousbevacizumab
AT iyervivekn mobilemitralandaorticvalvularmassesinpatientswithhereditaryhemorrhagictelangiectasiareceivingintravenousbevacizumab

Ejemplares similares